New pill shows promise for hard-to-treat lung cancer in early trial
NCT ID NCT04858958
First seen Nov 19, 2025 · Last updated May 16, 2026 · Updated 19 times
Summary
This early-stage study tests a drug called furmonertinib in 30 people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). Some participants have already tried other treatments, while others are new to therapy. The goal is to see how well the drug shrinks tumors and to check for side effects at two different doses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NSCLC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Shanghai Chest hospital
Shanghai, China
Conditions
Explore the condition pages connected to this study.